Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

ETR/BRM stock hub

ETR/BRM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ETR/BRMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

97.4B

Deutsche Börse Xetra

Market data

Live price

Current market quote for this ticker.

Current price

ETR/BRM

In the news

Latest news · ETR/BRM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.1

P25 12.3P50 15.7P75 20.2

Trailing P/E15.4

P25 16.4P50 20.9P75 30.4

ROE38.7

P25 -6.7P50 8.5P75 17.2

ROIC20.9

P25 -1.7P50 8.5P75 17.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ETR/BRM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

237

Groups with data

Currency

USD

Showing 237 of 237 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	32,500
Employees Change	-1,600%
Employees Change Percent	-4.69
Enterprise value	EUR 127.7B
Exchange	Deutsche Börse Xetra
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	US1101221083
Last refreshed	2026-05-10
Market cap	EUR 97.4B
Price	EUR 47.79
Price currency	EUR
Rev Per Employee	1,293,798.11x
Sector	Healthcare
Sic	2834
Symbol	etr/BRM
Website	https://www.bms.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.48%
EV Earnings	20.24x
EV/EBIT	9.77x
EV/EBITDA	7.75x
EV/FCF	12.36x
EV/Sales	3.1x
FCF yield	10.6%
Forward P/E	9.08x
P/B ratio	5.59x
P/E ratio	15.44x
P/S ratio	2.32x
PE Ratio10 Y	39.48x
PE Ratio3 Y	16.73x
PE Ratio5 Y	19.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	31.56%
EBITDA Margin	39.14%
FCF margin	24.56%
Gross margin	71.98%
Gross Profit	EUR 30.3B
Gross Profit Growth	-1.91%
Gross Profit Growth Q	-1.25%
Gross Profit Growth3 Y	-1.01%
Gross Profit Growth5 Y	0.44%
Net Income	EUR 6.3B
Net Income Growth	34.25%
Net Income Growth Q	9%
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Net Income Growth3 Y	-0.16%
Pretax Margin	19.79%
Profit Margin	15.01%
Profit Per Employee	EUR 194,142
Profitable Years	1
ROA	10.69
Roa5y	6.51
ROCE	22.73
ROE	38.73
Roe5y	13.18
ROIC	20.88
Roic5y	14.63

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.88%
Cagr15y	9.84%
Cagr1y	19.13%
Cagr3y	-3.74%
Cagr5y	1.9%
Div CAGR10	4.7%
Div CAGR3	0.2%
Div CAGR5	5.95%
EPS Growth	33.74
EPS Growth Q	9.17
EPS Growth Quarters	3
EPS Growth Years	1
EPS Growth3 Y	1.37
FCF Growth	-9%
FCF Growth Q	-55.31%
FCF Growth3 Y	2.43%
FCF Growth5 Y	-2.04%
OCF Growth	-7.02%
OCF Growth Q	-43.5%
OCF Growth10 Y	29.83%
OCF Growth3 Y	2.87%
OCF Growth5 Y	-0.93%
Revenue Growth	1.78x
Revenue Growth Q	2.57x
Revenue Growth Quarters	4x
Revenue Growth Years	0x
Revenue Growth3 Y	1.88x
Revenue Growth5 Y	2.52x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.54
Assets	EUR 75B
Cash	EUR 9.1B
Current Assets	EUR 23.1B
Current Liabilities	EUR 16.2B
Debt	EUR 40.3B
Debt EBITDA	EUR 2.4
Debt Equity	EUR 2.31
Debt FCF	EUR 3.9
Equity	EUR 17.4B
Interest Coverage	8.48
Liabilities	EUR 57.6B
Long Term Assets	EUR 51.9B
Long Term Liabilities	EUR 41.3B
Net Cash	EUR -30.9B
Net Cash By Market Cap	EUR -31.67
Net Debt EBITDA	EUR 1.88
Net Debt Equity	EUR 1.77
Net Debt FCF	EUR 2.99
Tangible Book Value	EUR -17.3B
Tangible Book Value Per Share	EUR -8.46
WACC	4.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.42
Inventory Turnover	5.01
Net Working Capital	EUR 61.6M
Quick ratio	1.18
Working Capital	EUR 7B
Working Capital Turnover	EUR 5.7

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.47%
Dividend Growth	-5.7%
Dividend Growth Years	4%
Dividend per share	EUR 2.14
Dividend Years	30
Dividend Yield	4.47%
Ex Div Date	2026-04-02
Last Dividend	EUR 0.54
Payout Frequency	Quarterly
Payout Ratio	69.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	9.2%
1Y total return	19.12%
200-day SMA	44.66
3Y total return	-10.81%
50-day SMA	50.76
50-day SMA vs 200-day SMA	50over200
5Y total return	9.85%
All Time High	80.5
All Time High Change	-40.64%
All Time High Date	2022-11-09
All Time Low	12.01
All Time Low Change	297.88%
All Time Low Date	2008-10-10
ATR	1.02
Beta	0.26
Ch YTD	3.89
High	47.96
High52	54.02
High52 Date	2026-03-05
High52ch	-11.54%
Low	47.47
Low52	36.6
Low52 Date	2025-10-29
Low52ch	30.56%
Ma50ch	-5.86%
Price vs 200-day SMA	7%
RSI	38.92
RSI Monthly	49.51
RSI Weekly	50.41
Sharpe ratio	0.68x
Sortino ratio	1.26
Total Return	4%
Tr YTD	6.21
Tr15y	308.49%
Tr1m	-4.85%
Tr1w	-2.33%
Tr3m	-7.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 13.3B
Operating Income Growth	38.03
Operating Income Growth Q	7.35
Operating Income Growth3 Y	16.68
Operating Income Growth5 Y	15.03
Operating margin	31.56

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,038,886,888%
Net Borrowing	-4,852,038,564
Shares Insiders	0.05%
Shares Institutions	83.08%
Shares Qo Q	0.29%
Shares Yo Y	0.47%
Short Ratio	2.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 9.8B
Average Volume	1,462.65x
Bv Per Share	8.52
CAPEX	EUR -1.2B
Ch10y	-22.7
Ch15y	151.6
Ch1m	-4.85
Ch1w	-2.33
Ch1y	13.49
Ch3m	-8.33
Ch3y	-22.3
Ch5y	-10.06
Ch6m	18.15
Change	0.96%
Change From Open	0.2
Close	47.33
Days Gap	0.76
Depreciation Amortization	3,116,260,350
Dollar Volume	6,212
Earnings Date	2026-04-30
EBIT	EUR 13.3B
EBITDA	EUR 16.5B
EPS	EUR 3.1
F Score	7
FCF	EUR 10.3B
FCF EV Yield	8.09x
Financing CF	-9,466,579,500
Fiscal Year End	December
Founded	1,887
Goodwill	18,434,693,880
Graham Number	24.39921
Graham Upside	-48.94
Income Tax	EUR 2B
Investing CF	-3,264,517,200
Is Primary Listing	0
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Lynch Fair Value	EUR 15.47
Lynch Upside	-67.62
Ma150	46.26
Ma150ch	3.3%
Ma20	49.58
Ma20ch	-3.62%
Net CF	-1,120,551,600
Open	47.69
P FCF Ratio	9.43
P OCF Ratio	8.44
Payment Date	2026-05-01
Position In Range	64.29
Ppne	7,789,378,932
Price Date	2026-05-08
Price EBITDA	EUR 5.92
Relative Volume	0.09x
Revenue	42,048,438,600x
SBC By Revenue	1.14x
Share Based Comp	481,351,500
Tax By Revenue	4.79x
Tax Rate	24.22%
Tr6m	20.78%
Volume	130
Z Score	2.48

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

ETR/BRM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+4.5%

$2.14 annual per share

Payout ratio

+69.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+6.0%

4 consecutive years of growth

Total shareholder yield

+4.0%

Next ex-dividend date: 2026-04-02

Performance

ETR/BRM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ETR/BRM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+83.1%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ETR/BRM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.9

Neutral momentum band

Price vs 200-day MA

+7.0%

50/200-day relationship not available

Beta (5Y)

0.26

Less volatile than the market

Sharpe ratio

0.68

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ETR/BRM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current etr/BRM stock rating?

etr/BRM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full etr/BRM analysis?

The full report lives at /stocks/etr/BRM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for etr/BRM?

The latest report frames etr/BRM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the etr/BRM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.